{"id":"ex039","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"As a drug in Phase 2 trials, EX039's specific biological interactions and pathways are still being studied to determine its precise mode of action.","oneSentence":"EX039's mechanism of action is currently under investigation and not fully characterized.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:00:05.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05413655","phase":"PHASE2","title":"A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease","status":"RECRUITING","sponsor":"Excelsior","startDate":"2022-08-08","conditions":"Alzheimer Disease","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EX039","genericName":"EX039","companyName":"Excelsior","companyId":"excelsior","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}